These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35395757)

  • 1. Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia.
    Fu AZ; Pesa JA; Lakey S; Benson C
    BMC Psychiatry; 2022 Apr; 22(1):250. PubMed ID: 35395757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study.
    Mahlich J; Olbrich K; Wilk A; Wimmer A; Wolff-Menzler C
    Clin Drug Investig; 2020 Apr; 40(4):355-375. PubMed ID: 32152867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
    Carswell C; Wheeler A; Vanderpyl J; Robinson E
    Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data.
    Munday J; Greene M; Chang E; Hartry A; Yan T; Broder MS
    Curr Med Res Opin; 2019 Jul; 35(7):1231-1239. PubMed ID: 30649965
    [No Abstract]   [Full Text] [Related]  

  • 7. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
    Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
    Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health resource utilization and cost before versus after initiation of second-generation long-acting injectable antipsychotics among adults with schizophrenia in Alberta, Canada: a retrospective, observational single-arm study.
    Wong KO; Klarenbach SW; Martins KJB; Chue P; Dursun SM; Snaterse M; Guigue A; So H; Luu H; Vu K; Richer L
    BMC Psychiatry; 2022 Jul; 22(1):444. PubMed ID: 35780116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia.
    Cai C; Kozma C; Patel C; Benson C; Yunusa I; Zhao P; Reeder G; Narasimhan M; Bank RL
    J Manag Care Spec Pharm; 2024 Jun; 30(6):549-559. PubMed ID: 38824623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia.
    Lauriello J; Weiden PJ; Gleeson CD; Shah A; Boulanger L; Jariwala-Parikh K; Hedgeman E; O'Sullivan AK
    CNS Drugs; 2021 Oct; 35(10):1123-1135. PubMed ID: 34546558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
    Joshi K; Pan X; Wang R; Yang E; Benson C
    Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
    Lin D; Thompson-Leduc P; Ghelerter I; Nguyen H; Lafeuille MH; Benson C; Mavros P; Lefebvre P
    CNS Drugs; 2021 May; 35(5):469-481. PubMed ID: 33909272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral.
    Offord S; Wong B; Mirski D; Baker RA; Lin J
    J Med Econ; 2013; 16(2):231-9. PubMed ID: 23163287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
    Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States.
    Patel C; Pilon D; Gupta D; Morrison L; Lafeuille MH; Lefebvre P; Benson C
    J Med Econ; 2022; 25(1):792-807. PubMed ID: 35635250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
    Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
    J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
    Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
    J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.